Engineering a Therapy‐Induced “Immunogenic Cancer Cell Death” Amplifier to Boost Systemic Tumor Elimination
Source abstract
Abstract
Abstract Immunogenic cancer cell death (ICD) is drawing worldwide attention as it allows dying cancer cells to regulate the host's anti‐tumor immune system and awaken immunosurveillance. Thus, effectively activating therapy‐induced ICD is of great clinical significance to raise systemic anti‐tumor immunity and eradicate post‐treatment/abscopal cancer tissues. Enhanced cytotoxic reactive oxygen species (ROS) generation in cancer therapy has been positively correlated to ICD induction, which inspires design of a therapy‐induced ICD amplifier. The nanohybrid amplifier (FeOOH@STA/Cu‐LDH) is devised based on Cu‐containing layered double hydroxide (Cu‐LDH), incorporating ROS inducer (FeOOH nanodots), ROS generation booster (Cu‐LDH for photothermal therapy), and heat shock protein inhibitor (STA). Treating 4T1 tumor cells with this amplifier translocates calreticulins (CRT, one of main ICD signals) on the surface of dying cancer cells, which achieves the maximum at fever‐type temperature (40–42 °C). To demonstrate immunotherapeutic efficacy of this nanohybrid, 4T1 tumor‐bearing mouse model is established with primary and abscopal tumors. Significantly, only one treatment with the ICD amplifier eradicates the primary tumor and inhibits the abscopal tumor growth upon fever‐type heating and induces more cytotoxic T lymphocytes in abscopal tumors and spleens after treatment for 1 week. This research thus provides a new insight into nanomaterial‐mediated tumor immunotherapy.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Advanced Nanomaterials in Catalysis · Extracellular vesicles in disease
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Australian Institute for Bioengineering and Nanotechnology The University of Queensland Brisbane QLD 4072 Australia
School of Chemical Engineering Australian Centre for NanoMedicine The University of New South Wales Sydney NSW 2052 Australia
Funding
National Health and Medical Research Council · Australian Research Council
References (62)
Show source-provided references
1. 10.1038/nrclinonc.2016.16810.1038/nrclinonc.2016.168 ↗
2. 10.1126/science.271.5256.173410.1126/science.271.5256.1734 ↗
3. 10.1126/science.116006210.1126/science.1160062 ↗
4. 10.1038/nature2134910.1038/nature21349 ↗
5. 10.1016/S0140-6736(18)30533-610.1016/S0140-6736(18)30533-6 ↗
6. 10.1158/2326-6066.CIR-17-005510.1158/2326-6066.CIR-17-0055 ↗
7. 10.1002/ange.20180759510.1002/ange.201807595 ↗
8. Angew. Chem. Int. Ed.2018 57 11764;10.1002/anie.201883011 ↗
9. 10.1038/nri.2016.10710.1038/nri.2016.107 ↗
10. 10.1038/nrc395810.1038/nrc3958 ↗
11. 10.1038/nrc338010.1038/nrc3380 ↗
12. 10.1038/s41467-017-00424-810.1038/s41467-017-00424-8 ↗
13. 10.1002/ange.20151003110.1002/ange.201510031 ↗
14. Angew. Chem. Int. Ed.2016 55 2101;10.1002/anie.201682111 ↗
15. 10.1002/adma.20170168310.1002/adma.201701683 ↗
16. 10.1021/acs.chemrev.8b0062610.1021/acs.chemrev.8b00626 ↗
17. 10.1016/j.apcatb.2016.06.00910.1016/j.apcatb.2016.06.009 ↗
18. 10.1002/smll.20180067810.1002/smll.201800678 ↗
19. 10.1021/acsami.9b1713710.1021/acsami.9b17137 ↗
20. 10.1002/adfm.20180138910.1002/adfm.201801389 ↗
21. 10.1039/C8CS00618K10.1039/C8CS00618K ↗
22. 10.1039/C7CS00522A10.1039/C7CS00522A ↗
23. Chen W. R. · Cancer Res. · 2001 · 61 · 459
24. 10.1038/s41467-018-03473-910.1038/s41467-018-03473-9 ↗
25. Mahadevan S. V. · 2012 · 37510.1017/CBO9780511852091 ↗
26. 10.1021/ja508641z10.1021/ja508641z ↗
27. 10.1002/adfm.20150304610.1002/adfm.201503046 ↗
28. 10.1016/S1040-8428(01)00179-210.1016/S1040-8428(01)00179-2 ↗
29. 10.1126/sciimmunol.aan569210.1126/sciimmunol.aan5692 ↗
30. 10.1016/j.biomaterials.2019.11928010.1016/j.biomaterials.2019.119280 ↗
31. 10.1002/adma.20170358810.1002/adma.201703588 ↗
32. 10.1002/ange.20130655710.1002/ange.201306557 ↗
33. Angew. Chem. Int. Ed.2013 52 13047;10.1002/anie.201390054 ↗
34. 10.1002/adfm.20160003110.1002/adfm.201600031 ↗
35. 10.1126/scitranslmed.aar334210.1126/scitranslmed.aar3342 ↗
36. 10.1016/j.biomaterials.2018.05.05510.1016/j.biomaterials.2018.05.055 ↗
37. 10.1016/j.biomaterials.2013.12.09510.1016/j.biomaterials.2013.12.095 ↗
38. 10.1002/1521-3757(20001117)112:22<4207::AID-ANGE4207>3.0.CO;2-H10.1002/1521-3757(20001117)112:22<4207::AID-ANGE4207>3.0.CO;2-H ↗
39. Angew. Chem. Int. Ed.2000 39 4042.
40. 10.1002/ange.20181370210.1002/ange.201813702 ↗
41. Angew. Chem. Int. Ed.2019 58 2407.10.1002/anie.201984311 ↗
42. 10.1002/ange.20171254910.1002/ange.201712549 ↗
43. Angew. Chem. Int. Ed.2018 57 2672;10.1002/anie.201883011 ↗
44. 10.1038/nmat211810.1038/nmat2118 ↗
45. 10.1002/adma.1993005020410.1002/adma.19930050204 ↗
46. 10.1007/s11237-013-9297-710.1007/s11237-013-9297-7 ↗
47. 10.1038/nbt.333010.1038/nbt.3330 ↗
48. 10.1021/ac301142c10.1021/ac301142c ↗
49. 10.1021/ja00020a02110.1021/ja00020a021 ↗
50. 10.1038/nnano.2012.9010.1038/nnano.2012.90 ↗
51. 10.1038/nnano.2007.26010.1038/nnano.2007.260 ↗
52. 10.1002/advs.20180115510.1002/advs.201801155 ↗
53. 10.1021/jacs.7b0555910.1021/jacs.7b05559 ↗
54. 10.1038/nm152310.1038/nm1523 ↗
55. 10.1002/adma.20170037310.1002/adma.201700373 ↗
56. 10.1158/1078-0432.CCR-14-252010.1158/1078-0432.CCR-14-2520 ↗
57. 10.1158/1078-0432.CCR-09-289110.1158/1078-0432.CCR-09-2891 ↗
58. 10.1038/s41467-019-11269-810.1038/s41467-019-11269-8 ↗
59. 10.1038/ncomms1319310.1038/ncomms13193 ↗
60. 10.1038/s41467-017-00424-810.1038/s41467-017-00424-8 ↗
61. 10.1023/A:102450821566210.1023/A:1024508215662 ↗
62. 10.1021/jacs.8b1090410.1021/jacs.8b10904 ↗